Saxum Surgical, Inc.
$48.5K 331 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Protega Pharmaceutials Inc
Protega Pharmaceutials Inc reported $48,456.86 across General Payments, Research, and Ownership to 1,404 physicians and teaching hospitals across 1,404 transactions.
- $48.5K Below-median payer
- All-tracks total
- 1,404 Top quartile volume
- Transactions
- 1,404 Top quartile reach
- Recipients
- +$5.1K
- General Payments vs PY2023
Protega Pharmaceutials Inc reported $48,456.86 across all CMS Open Payments tracks (General + Research + Ownership) to 1,404 physicians and teaching hospitals in Program Year 2024 - ranking #1359 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $48,456.86, averaging $34.51 per recipient.
Protega Pharmaceutials Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
19/100
Total payments
F
10/100
Transaction volume
F
20/100
Physician reach
F
21/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer protega-pharmaceutials-inc Protega Pharmaceutials Inc
$48.5K · #1359/1,925 · 0.0% industry · PY2024
- TOT $48.5K
- RANK #1359
- SHARE 0.0%
- TXN 1,404
- RCP 1,404
- CAT 2
- GEN $48.5K
- ΔGEN +$5.1K
- TOP1 3.4%
- PY 2024
Volume peers
Nearest volume peer: Saxum Surgical, Inc. ($48.5K)
Protega Pharmaceutials Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Protega Pharmaceutials Inc's CMS-reported General Payments increased by $5.1K (+11.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PROTEGA PHARMACEUTIALS INCPY2023: PROTEGA PHARMACEUTIALS INCPY2024: PROTEGA PHARMACEUTIALS INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $43,389.87
- PY2024
- $48,456.86
What the Data Shows for Protega Pharmaceutials Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Protega Pharmaceutials Inc that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
1,383 transactions worth $35.9K make "Food and Beverage" the top general-payment category in the 2-category breakdown below, 74.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 2 types of general payments, Protega Pharmaceutials Inc's largest category was "Food and Beverage" at $35.9K - 74.2% of General Payments.
How Protega Pharmaceutials Inc divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $35.9K | 1,383 | 74.2% |
| Honoraria | $12.5K | 21 | 25.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $5,743.45 (11.9%) of $48,456.86 in this company's General Payments records across 697 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Protega Pharmaceutials Inc
The five named recipients with the highest reported General Payments from this company
- 1
Russell C Feit
$1,650.00 across 2 reported transactions
- 2
Alexander Beyzer
$1,383.22 across 7 reported transactions
- 3
Romanth Md Waghmarae
$964.66 across 5 reported transactions
- 4
Irfan Alladin
$884.00 across 21 reported transactions
- 5
Collin Patrick Duffy
$861.57 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Protega Pharmaceutials Inc ranks #1359 of 1,925 by total payments (bottom 29% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,734 of 1,838 by HHI (bottom 6% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Ironshore Pharmaceuticals Inc. : $1.1M total payments, HHI 74
- Bayer Puerto Rico Inc. : $18.3K total payments, HHI 73
- Fisher & Paykel Healthcare Inc : $225.2K total payments, HHI 73
- ViiV Healthcare Company : $8.9M total payments, HHI 73
- Sanofi-Aventis U.s. LLC : $9.2M total payments, HHI 72
- Dermavant Sciences, Inc. : $6.7M total payments, HHI 71
- Protega Pharmaceutials Inc (this company) : $48.5K total payments, HHI 71
- Merck Sharp & Dohme LLC : $23.2M total payments, HHI 69
- Life Molecular Imaging Ltd : $8.0K total payments, HHI 68
- Ironwood Pharmaceuticals, Inc : $659.4K total payments, HHI 68
- Novus Surgical Consultants : $122.1K total payments, HHI 68
- UCB, Inc. : $18.4M total payments, HHI 68
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Protega Pharmaceutials Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Protega Pharmaceutials Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Protega Pharmaceutials Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Vibrant Gastro, Inc.
$48.6K 96 recipients
Compare payment profiles
Bodycad USA Corp
$48.6K 51 recipients
Compare payment profiles
Activ Surgical, Inc.
$48.3K 91 recipients
Compare payment profiles
FloSpine LLC
$48.7K 25 recipients
Compare payment profiles
Alon Medical Technology
$48.8K 496 recipients
Compare payment profiles
Put this to use
Protega Pharmaceutials Inc ranks #1359 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Protega Pharmaceutials Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.